Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance. Issue 14 (6th December 2022)

• Record Type: Journal Article
• Authors: Major, Ajay; Wright, Rachel; Hlubocky, Fay J.; Smith, Sonali M.; Prochaska, Micah T.
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 14(2022)
• Page Start: 3331
• Page End: 3339
• Publication Date: 2022-12-06
• Subjects: Patient-reported outcomes -- quality of life -- non-Hodgkin lymphoma -- active surveillance; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2123225
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: There are limited data describing the impact of active surveillance on longitudinal health-related quality of life (HRQoL) in patients with indolent non-Hodgkin lymphomas (NHL). A cohort of untreated indolent NHL patients completed FACT-LYM questionnaires at 6, 12, 18, 24, and 36 months after diagnosis. Longitudinal FACT-LYM scores were analyzed by ANOVA and generalized linear mixed models. Indolent NHL scores were compared to norm general population scores. A total of 52 patients were identified, of which 46 (88%) remained on active surveillance at 36 months. There was no significant change in any of the FACT-LYM scores over 36 months. As compared to the general population, indolent NHL patients had higher, clinically meaningful scores in physical, functional, and social well-being, but not emotional well-being. Patients with indolent NHL on active surveillance have globally preserved HRQoL for up to 3 years after diagnosis. Emotional well-being continues to be an unmet need during active surveillance.